Stockreport

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Edesa Biotech, Inc. - Common Shares  (EDSA) 
PDF Study met primary and secondary endpointsParidiprubart demonstrated a relative reduction in the risk of death of 25%Treatment provided patients with clinically meaningfu [Read more]